微循環(huán)與血管活性藥_第1頁(yè)
微循環(huán)與血管活性藥_第2頁(yè)
微循環(huán)與血管活性藥_第3頁(yè)
微循環(huán)與血管活性藥_第4頁(yè)
微循環(huán)與血管活性藥_第5頁(yè)
已閱讀5頁(yè),還剩34頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

Sepsis微循環(huán)

與血管活性藥奚佳瑞2011年2月5/8/20241微循環(huán)與血管活性藥引言Sepsis:疑問(wèn):臨床上血流動(dòng)力學(xué)穩(wěn)定、氧傳遞指標(biāo)等均可,但依然進(jìn)展、乳酸升高?早期亦已存在微循環(huán)功能障礙?。?/p>

5/8/20242微循環(huán)與血管活性藥引言微循環(huán):如此重要、關(guān)鍵應(yīng)成為危重患者復(fù)蘇中的一個(gè)關(guān)鍵指標(biāo)但:傳統(tǒng)的評(píng)價(jià)指標(biāo)難以準(zhǔn)確評(píng)價(jià)微循環(huán)!5/8/20243微循環(huán)與血管活性藥主要問(wèn)題:1.有什么新的方法監(jiān)測(cè)微循環(huán)?2.現(xiàn)有血管活性藥物微循環(huán)的影響如何?5/8/20244微循環(huán)與血管活性藥微循環(huán)的結(jié)構(gòu)直徑<300um的血管100億個(gè)毛細(xì)血管血管表面積>500m2組成:微動(dòng)脈,后微動(dòng)脈,毛細(xì)血管前括約肌,真毛細(xì)血管、通血毛細(xì)血管、動(dòng)靜脈交通支、微靜脈

5/8/20245微循環(huán)與血管活性藥微循環(huán)的功能及分類(lèi)1.迂回通路:物質(zhì)交換,交替開(kāi)放(又稱(chēng)營(yíng)養(yǎng)通路)2.直捷通路:不進(jìn)行物質(zhì)交換,血液快速回流,骨骼肌多見(jiàn)3.動(dòng)靜脈短路:不進(jìn)行物質(zhì)交換,皮膚多見(jiàn)5/8/20246微循環(huán)與血管活性藥5/8/20247微循環(huán)與血管活性藥Sepsis時(shí)微循環(huán)的改變1994年,LamC等對(duì)血壓穩(wěn)定的鼠sepsis微循環(huán)活體顯微鏡在體觀察,發(fā)現(xiàn)sepsis時(shí):1.灌注毛細(xì)血管密度減少,血流停止的毛細(xì)血管數(shù)增加;2.灌注毛細(xì)血管空間分布不均,平均毛細(xì)血管間距增加2002年,DeBacker等利用OPS成像觀察sepsis舌下微循環(huán),發(fā)現(xiàn):1.微血管密度顯著減少,血流停滯和血流灌注間斷的小血管比例增加;2.各區(qū)域間灌注血管的變異系數(shù)明顯大于健康志愿者

DeBackerD,CreteurJ,PreiserJC,etal.Microvascularbloodflowisalteredinpatientswithsepsis.AMJRespirCritCareMed,2002,166:98-1045/8/20248微循環(huán)與血管活性藥

OPS圖像5/8/20249微循環(huán)與血管活性藥Sepsis時(shí)微循環(huán)的改變特征:1.adecreaseincapillarydensity2.anincreaseinheterogeneityofperfusionwithnon-perfusedinclosevicinitytowell-perfusedcapillaries后果?5/8/202410微循環(huán)與血管活性藥Tissuestoleratebetterahomogeneous

decreaseinbloodflowbetterthanaheterogeneousoneDanielDeBacker,GustavoOspina-Tascon,etal.IntensiveCareMed(2010)36:1813–1825.5/8/202411微循環(huán)與血管活性藥5/8/202412微循環(huán)與血管活性藥HowtoevaluatethemicrocirculationIntensiveCareMed(2010)36:1813–1825.5/8/202413微循環(huán)與血管活性藥NailfoldvideocapillaroscopyThefirstmethodusedatthebedsidethenailfoldareaisverysensitivetochangesintemperature:onecancontrolambientbutnotbodytemperature.PeripheralvasoconstrictioncanalsooccurduringchillsandacutecirculatoryfailureOflimiteduseincriticallyillpatients.5/8/202414微循環(huán)與血管活性藥LaserDopplerMainlimitation:measuresflowinavariablevolumeoftissue,unabletodetectitinindividualvesselsSamplingvolume:0.5and1mm3,about50vesselsCannotshowtheheterogeneity5/8/202415微循環(huán)與血管活性藥SvO2VenousO2saturationcanbehighorlowforthesamedegreeofmicrovascularshunting—canbemisleadingSeveralstudieshaveshownthatmeasuringSvO2doesnotprovidemuchinformationaboutmicrovascularalterations---PodbregarM,MozinaH.Skeletalmuscleoxygensaturationdoesnotestimatemixedvenousoxygensaturationinpatientswithsevereleftheartfailureandadditionalseveresepsisorsepticshock.CritCare2007,11:R6MarikPE,BankovA,Sublingualcapnometryversustraditionalmarkersoftissueoxygenationincriticallyillpatients.CritCareMed2003,31:818–8225/8/202416微循環(huán)與血管活性藥GastrictonometryAgastricPCO2gapabove20mmHgdiscriminatedsurvivorsfromnon-survivors-------LevyB,GawalkiewiczP.CritCareMed2003,31:474–48

GastricPCO2gap---mostlyreflectsgutmucosalmicrocirculation----Insepsis,nocorrelationbetweenthegastricPCO2gapandtotalsplanchnicperfusionDuodeno-gastricrefluxandfeedingcaninterfere5/8/202417微循環(huán)與血管活性藥LactateTimelag-------Cannotdetectalterationsinmicrovascularperfusionbeforetheyareassociatedwithcellularhypoxia5/8/202418微循環(huán)與血管活性藥OPS/SDFOPS成像:正交偏振光譜成像orthogonalpolarizationspectralimaging原理:利用血細(xì)胞對(duì)偏振入射綠光產(chǎn)生消偏振光散射和對(duì)正偏振光的成像特征,能在皮下0.5mm深度內(nèi)產(chǎn)生高清晰度和高分辨率的成像。局限性:敏感性偏差;需具備高能光源,難以應(yīng)用到臨床。5/8/202419微循環(huán)與血管活性藥OPS/SDFSDF成像:旁流暗場(chǎng)成像,sidestreamdark-field,2007年開(kāi)始應(yīng)用于臨床優(yōu)點(diǎn):更加清晰所需能量小,可以方便的使用電池床邊操作

5/8/202420微循環(huán)與血管活性藥SDFimage5/8/202421微循環(huán)與血管活性藥OPS/SDFAdvantage:1.visible2.differentvariablescanbeobservedandbemeasured---vasculardensity,heterogeneityofperfusion,microvascularbloodflowTheconsensusadvisesreportingofPVD,PPV,MFIandheterogeneityindex,inordertodescribethefunctionalperfusionofthemicrocirculation.-------Howtoevaluatethemicrocirculation:reportofaroundtableconference,CriticalCare2007,11:R101

5/8/202422微循環(huán)與血管活性藥血管活性藥物對(duì)微循環(huán)的影響Vasopressors:Norepinephrine,Epinephrine,VasopressinInotropes:Dopamine,Dobutamine,Vasodilators:Nitroglycerin,Prostacyclin5/8/202423微循環(huán)與血管活性藥NEdoesnotimprovemicrocirculatorybloodflow20septicshockpatientsBasalmeasurementofMAP65mmHg,NEwastitratedtoreachaMAPof75mmHg,then85mmHgSublingualmicrocirculationwasevaluatedbySDFimagingDubinA,PozoMO,etal.Increasingarterialbloodpressurewithnorepinephrinedoesnotimprovemicrocirculatorybloodflow:aprospectivestudy.Critcare,2009,13(3):R925/8/202424微循環(huán)與血管活性藥NEdoesnotimprovemicrocirculatorybloodflow5/8/202425微循環(huán)與血管活性藥NEdoesnotimprovemicrocirculatorybloodflow5/8/202426微循環(huán)與血管活性藥NEdoesnotimprovemicrocirculatorybloodflow1.NEdoesnotimprovemicrocirculataryperfusionfurtherincreaseMAPfrom65mmHg.2.ReductionsintheperfusedcapillarydensitiesfurtherincreaseMAPfrom65mmHg.結(jié)論:使用去甲升高M(jìn)AP并不是改善感染性休克患者微循環(huán)的一個(gè)恰當(dāng)方法,反而可能對(duì)患者有害。5/8/202427微循環(huán)與血管活性藥TheeffectofincreasingdosesofNEontissueoxygenationandmicrovascularflowinpatientswithsepticshock16septicshockpatientsNEfrom0.18to0.25,0.35,0.41ug/kg.minMAPfrom60-70-80-90mmHgSDFimaging

ShamanJhanji,etal.CritcareMed2009;37:1961-19665/8/202428微循環(huán)與血管活性藥TheeffectofincreasingdosesofNEontissueoxygenationandmicrovascularflowinpatientswithsepticshockMAP高于60-65mmHg不能改善感染性休克患者微循環(huán)增加NE對(duì)感染性休克患者微循環(huán)無(wú)明顯影響

ShamanJhanji,etal.CritcareMed2009;37:1961-19665/8/202429微循環(huán)與血管活性藥多巴胺對(duì)微循環(huán)的影響1.1Meier-HellmannA,BredleDL,SpechtM,SpiesC,HannemannL,ReinhartK(1997)Theeffectsoflow-dosedopamineonsplanchnicbloodflowandoxygenuptakeinpatientswithsepticshock.IntensiveCareMed23:31–371.2OlsonD,PohlmanA,HallJB(1996)Administrationoflow-dosedopaminetononoliguricpatientswithsepsissyndromedoesnotraiseintramucosalgastricpHnorimprovecreatinineclearance.AmJRespirCritCareMed154:1664–16702.MarikPE,MohedinM(1994)Thecontrastingeffectsofdopamineandnorepinephrineonsystemicandsplanchnicoxygenutilizationinhyperdynamicsepsis.JAMA272:1354–13575/8/202430微循環(huán)與血管活性藥NG對(duì)微循環(huán)的影響5/8/202431微循環(huán)與血管活性藥NGinsepticshockafterintravascularvolumeresuscitation8septicshockpatientsMAPwasgreaterthan60mmHgandCVPgreaterthan12mmHgafterinfusionofcrystalloidsandcolloids,andthelowestpossibledoseofdopamineNG:anintravenousloadingdoseof0·5mg,thensubsequentcontinuousinfusionof2mg/hOPS:usedtoproduceimagesofsublingualmicrocirculationLancet2002;360:1395-13965/8/202432微循環(huán)與血管活性藥NGinsepticshockafterintravascularvolumeresuscitation5/8/202433微循環(huán)與血管活性藥OPSimages5/8/202434微循環(huán)與血管活性藥70個(gè)Severesepsis和septicshock患者充分復(fù)蘇后給予硝酸甘油或安慰劑SDF評(píng)估舌下微循環(huán)主要終點(diǎn):sublingualmicrocirculatorybloodflowofsmallvesselsCritCareMed2010;38:93-1005/8/202435微循環(huán)與血管活性藥Microvascularvariablesovertime5/8/202436微循環(huán)與血管活性藥TakeHomeMessage1.重視微循環(huán)檢測(cè)2.s

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論